{"id":"NCT00868452","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)","officialTitle":"A Randomized, 6-Week, Double-Blind, Placebo- Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2011-12","completion":"2012-01","firstPosted":"2009-03-25","resultsPosted":"2013-04-02","lastUpdate":"2014-04-17"},"enrollment":348,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Depression"],"interventions":[{"type":"DRUG","name":"lurasidone + (lithium or divalproex)","otherNames":[]},{"type":"DRUG","name":"Placebo + (lithium or divalproex)","otherNames":[]}],"arms":[{"label":"Lurasidone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe when added to treatment with lithium or Divalproex for the treatment of patients with bipolar I depression.","primaryOutcome":{"measure":"Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)","timeFrame":"Baseline, Week 6","effectByArm":[{"arm":"Lurasidone","deltaMin":-17.1,"sd":0.87},{"arm":"Placebo","deltaMin":-13.5,"sd":0.91}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":71,"countries":["United States","Czechia","France","Germany","India","Poland","Romania","Russia","South Africa","Ukraine"]},"refs":{"pmids":["24170221","38639433","37339360","27529375","27215976","26730454"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":183},"commonTop":["Nausea","Headache","Somnolence","Tremor","Insomnia"]}}